

January 09, 2025

To,
The Manager
Dept of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001

Dear Sir/Madam,

Subject : Outcome of the Board Meeting
Reference : Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015
Scrip : 511509

With reference to the above cited subject and our letter dated January 02, 2025 and January 04, 2025, we bring to your kind notice that the Board of Directors of the Company at their meeting held today, i.e. Thursday, January 09, 2025, *inter-alia*, transacted the following business:

1. Approved the Un-Audited Standalone & Consolidated Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2024.
2. Approved Raising of Funds by Preferential Issue of Convertible Equity Warrants to Certain Identified Promoter/Promoter Group and Non-Promoter Group/Entities.

The issuance and allotment of up to 1,00,00,000 (One Crore only) Convertible Equity Warrants ('Warrants'), carrying a right exercisable by Proposed Allottees to subscribe to one Equity Share (having face value of Rs. 10/- (Rupees Ten only)) per Warrant by way of preferential allotment on private placement basis to "Promoter/Promoter Group and Non-Promoter(Public Category)" ("Proposed Allottees"), as detailed below, at an issue price of Rs. 45/- (Rupees Forty-Five only) per Warrant, which is higher than the floor price determined in accordance with the provisions of Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations") payable in cash for an amount aggregating up to Rs. 45,00,00,000/- (Rupees Forty-Five Crore only) in such manner and on such terms and conditions as may be determined by the Board in accordance with SEBI ICDR Regulations and other applicable laws subject to approval of Members at the ensuing Extraordinary General Meeting and other necessary regulatory, statutory and other approvals, permissions and sanctions, as may be applicable.

Names of the Proposed Allottees of the Convertible Equity Warrants:

S.No.	Names of the Proposed Allottees	Category	Maximum no. of Warrants for the respective Allottee
1.	Viswanath Kompella	Promoter	6,00,000
2.	Kompella Lopa Mudra	Promoter Group	6,00,000
3.	Kompella Ramakrishna Paramahansa	Promoter Group	6,00,000
4.	Kompella Modini	Promoter Group	6,00,000
5.	Dwight Technologies Private Limited	Public	25,00,000
6.	Paraj Infrastructures Private Limited	Public	25,00,000
7.	Antique Infotech Private Limited	Public	26,00,000
		Total	1,00,00,000

Details as required under Regulation 30 of the Listing Regulations read with Master Circular issued by SEBI vide circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 ("Master Circular"), with respect to the preferential issue is enclosed as Annexure-I.

- Approved Notice of the Extra-Ordinary General Meeting (EGM No. 01/2024-2025), which is scheduled to be held on Friday, February 07, 2025 at 12:30 P.M. (noon) for obtaining the approval of the Members of the Company for the aforementioned matters, the Board of Directors of the Company has decided to hold an EGM of the Company on Friday, February 07, 2025 through OAVM/VC and has approved the draft notice of the EGM and matters related thereto to be issued to the shareholders for convening the EGM.

The notice of the said EGM will be sent separately to the stock exchange(s) and to the shareholders of the Company and will also be available on the Company's website at www.vivobio.com and on the website of the stock exchange i.e. BSE Limited in due course.

- The Company has fixed Friday, January 31, 2025 as the cut-off date for determining the eligibility of the Members entitled to vote by remote e-voting at the ensuing EGM of the Company schedule to be held on Friday, February 07, 2025 through OAVM/VC. The Company would be availing e-voting services of CDSL. The remote e-voting period begins on Monday, February 03, 2025 (09:00 A.M. IST) and ends on Thursday, February 06, 2025 (05:00 P.M. IST).

The meeting commenced at 05:30 p.m. and concluded at 06:25 p.m.

This is for your information and records.

Thanking You,

Yours faithfully

For Vivo Bio Tech Limited

A V Kiran
Company Secretary

Encl as above

Annexure-I

Details as required under Regulation 30 of the Listing Regulations read with Master Circular issued by SEBI vide circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 (“Master Circular”), with respect to the preferential issue.

S.No.	Particulars	Disclosure																																				
1.	Type of securities proposed to be Issued	Fully Convertible Equity Warrants (“Warrants”)																																				
2.	Type of issuance	Preferential Issue																																				
3.	Total number of securities proposed to be issued or total amount for which the securities will be issued	Up to 1,00,00,000 (One Crore only) Warrants at an issue price of Rs. 45/- (Rupees Forty-Five only) each to persons belonging to “Promoter/Promoter Group and Non-Promoter(Public Category)” for an amount aggregating up to Rs. 45,00,00,000/- (Rupees Forty-Five Crore only)																																				
4.	Name and number of the Investor(s)	<table border="1"> <thead> <tr> <th>S.No.</th> <th>Names of the Proposed Allottees</th> <th>Category</th> <th>Maximum no. of Warrants for the respective Allottee</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>Viswanath Kompella</td> <td>Promoter</td> <td>6,00,000</td> </tr> <tr> <td>2.</td> <td>Kompella Lopa Mudra</td> <td>Promoter Group</td> <td>6,00,000</td> </tr> <tr> <td>3.</td> <td>Kompella Ramakrishna Paramahamsa</td> <td>Promoter Group</td> <td>6,00,000</td> </tr> <tr> <td>4.</td> <td>Kompella Modini</td> <td>Promoter Group</td> <td>6,00,000</td> </tr> <tr> <td>5.</td> <td>Dwight Technologies Private Limited</td> <td>Public</td> <td>25,00,000</td> </tr> <tr> <td>6.</td> <td>Paraj Infrastructures Private Limited</td> <td>Public</td> <td>25,00,000</td> </tr> <tr> <td>7.</td> <td>Antique Infotech Private Limited</td> <td>Public</td> <td>26,00,000</td> </tr> <tr> <td></td> <td></td> <td>Total</td> <td>1,00,00,000</td> </tr> </tbody> </table>	S.No.	Names of the Proposed Allottees	Category	Maximum no. of Warrants for the respective Allottee	1.	Viswanath Kompella	Promoter	6,00,000	2.	Kompella Lopa Mudra	Promoter Group	6,00,000	3.	Kompella Ramakrishna Paramahamsa	Promoter Group	6,00,000	4.	Kompella Modini	Promoter Group	6,00,000	5.	Dwight Technologies Private Limited	Public	25,00,000	6.	Paraj Infrastructures Private Limited	Public	25,00,000	7.	Antique Infotech Private Limited	Public	26,00,000			Total	1,00,00,000
S.No.	Names of the Proposed Allottees	Category	Maximum no. of Warrants for the respective Allottee																																			
1.	Viswanath Kompella	Promoter	6,00,000																																			
2.	Kompella Lopa Mudra	Promoter Group	6,00,000																																			
3.	Kompella Ramakrishna Paramahamsa	Promoter Group	6,00,000																																			
4.	Kompella Modini	Promoter Group	6,00,000																																			
5.	Dwight Technologies Private Limited	Public	25,00,000																																			
6.	Paraj Infrastructures Private Limited	Public	25,00,000																																			
7.	Antique Infotech Private Limited	Public	26,00,000																																			
		Total	1,00,00,000																																			
5.	Issue price	Rs. 45/- (Rupees Forty-Five only)																																				
6.	Post allotment of																																					

	securities - outcome of the subscription.	Category	Pre preferential issue		Post preferential issue*	
			No of Shares	%	No of Shares	%
		Promoters and Promoter Group (A)	62,71,500	38.88	86,71,500	33.19
		Public (B)	98,57,020	61.12	1,74,57,020	66.81
		Non-Promoter-Non Public Shareholding (C)	0	0	0	0
		Total (A) + (B)+(C)	1,61,28,520	100	2,61,28,520	100
* The above post-issue shareholding is prepared to assume full conversion of Warrants into equity shares issued pursuant to this preferential issue						
7.	Intimation on conversion of securities or on lapse of the tenure of the instrument	The tenure of the Warrants shall not exceed 18 (eighteen) months from the date of allotment. Each warrant would be convertible into 1 Equity Share and the rights attached to Warrants can be exercised in one or more tranches, within 18 (eighteen months) from the date of allotment of such warrants. In the event that a Warrant holder does not exercise the Warrants within a period of 18 (eighteen) months from the date of allotment of such warrants, the unexercised Warrants shall lapse and the amount paid by that Warrant holder on such Warrants shall stand forfeited by the Company.				
8.	Nature of Consideration	Cash				
9.	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not applicable				

UN-AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE THIRD QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2024

S.No.	PARTICULARS	QUARTER ENDED						NINE MONTHS ENDED		YEAR ENDED
		31.12.2024		30.09.2024		31.12.2023		31.12.2024		31.03.2024
		Un-Audited	Audited	Un-Audited	Audited	Un-Audited	Audited	Un-Audited	Audited	Audited
I	Revenue from operations	1,221.25	1,203.51	1,284.89	1,284.89	3,438.18	3,369.29	4,545.12	3,88	
II	Other Income	0.85	463.10	2.97	465.18	3,903.36	3,372.26	4,549.00		
III	Total Income	1,222.10	1,666.61	1,287.86	1,757.07	7,341.54	6,741.55	9,094.12		
IV	Expenses									
	a) Increase/(decrease) in stock in trade and WIP	103.25	57.06	-19.67	177.52	-72.32	-80.13			
	b) Consumption of Raw materials	-	-	-	-	-	-			
	c) Purchase of traded goods	83.35	90.57	117.72	324.48	355.93	465.10			
	d) Employees Cost	321.64	344.34	294.95	900.23	799.97	1,068.31			
	e) Depreciation and amortisation	224.77	229.41	227.65	677.11	686.47	929.08			
	f) Finance Cost	183.76	206.11	222.17	582.31	625.95	777.79			
	g)Administrative Expenditure	159.14	152.41	254.20	486.55	713.68	982.81			
	Total	1,075.91	1,079.90	1,097.02	3,148.19	3,109.68	4,142.96			
V	Profit Before Tax & Exceptional Item (III-IV)	146.19	586.71	190.84	755.16	262.58	406.04			
	Exceptional Items	-	-	-	-	-	-			
	Prior Period Items	-	-	-	-	-	-			
VI	Profit Before Tax	146.19	586.71	190.84	755.16	262.58	406.04			
VII	Tax Expense									
	a. Current Tax	61.38	78.18	59.65	159.38	94.62	167.71			
	b. Deferred tax	2.81	(14.83)	(0.89)	(26.21)	(11.06)	(14.29)			
	Total Tax Expense	64.19	63.35	58.76	133.17	83.56	153.42			
	Net Profit After Tax (V-VI)	82.00	523.36	132.08	621.99	179.02	252.62			
VIII	Minority Interest	-	-	-	-	-	-			
IX	Other Comprehensive Income									
	a. Items that will be reclassified to profit or loss (Net of Tax)	-	-	-	-	-	-			
X	Total other Comprehensive Income(VIII+IX)	82.00	523.36	132.08	621.99	179.02	252.62			
XI	Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)	1,612.85	1,490.35	1,490.35	1,612.85	1,490.35	1,490.35			
XII	Earnings per equity share:									
	1)Basic	0.55	3.51	0.89	4.16	1.20	1.70			
	2)Diluted	0.55	3.51	0.89	4.16	1.20	1.51			

Place: Hyderabad
Date: January 09, 2025

For Vivo Bio Tech Limited



M. Kalyan Ram
Whole Time Director
DIN:02012580

UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE THIRD QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2024

S.No.	PARTICULARS	QUARTER ENDED						NINE MONTHS ENDED		YEAR ENDED
		31.12.2024		30.09.2024		31.12.2023		31.12.2024		31.03.2024
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited	
I	Revenue from operations	1,221.25	1,203.51	1,270.59	3,438.18	3,333.04	4,488.05			
II	Other Income	0.85	463.10	2.97	465.18	2.97	3.88			
III	Total Income	1,222.10	1,666.61	1,273.56	3,903.36	3,336.01	4,491.93			
IV	Expenses									
	a) Increase/(decrease) in stock in trade and WIP	103.25	57.06	-19.67	177.52	-72.32	-80.13			
	b) Consumption of Raw materials	-	-	-	-	-	-			
	c) Purchase of traded goods	83.35	90.57	117.72	324.48	355.93	465.10			
	d) Employees Cost	314.24	336.45	280.64	883.80	760.35	1,013.42			
	e) Depreciation and amortisation	224.77	229.41	227.65	677.11	686.47	929.08			
	f) Finance Cost	183.76	206.11	222.17	582.31	625.95	777.79			
	g) Administrative Expenditure	159.11	152.39	254.16	486.49	713.62	981.20			
	Total	1,068.48	1,071.99	1,082.67	3,131.70	3,070.00	4,086.46			
V	Profit Before Tax & Exceptional Items (III-IV)	153.62	594.62	190.89	771.66	266.01	405.47			
	Exceptional Items	-	-	-	-	-	-			
	Prior Period Items	-	-	-	-	-	-			
VI	Profit Before Tax	153.62	594.62	190.89	771.66	266.01	405.47			
VII	Tax Expense									
	a. Current Tax	61.38	78.18	59.65	159.38	94.62	167.54			
	b. Deferred tax	2.81	(14.83)	(0.89)	(26.21)	(11.06)	(14.29)			
	Total Tax Expense	64.19	63.35	58.76	133.17	83.56	153.25			
	Net Profit After Tax (V-VI)	89.43	531.27	132.13	638.49	182.45	252.22			
VIII	Other Comprehensive Income									
	a. Items that will be reclassified to profit or loss (Net of Tax)	-	-	-	-	-	-			
IX	Total other Comprehensive Income (VII+VIII)	89.43	531.27	132.13	638.49	182.45	252.22			
X	Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)	1,612.85	1,490.35	1,490.35	1,612.85	1,490.35	1,490.35			
XI	Earnings per equity share:									
	1) Basic	0.60	3.56	0.89	4.27	1.22	1.69			
	2) Diluted	0.60	3.56	0.89	4.27	1.22	1.51			

Place: Hyderabad
Date: January 09, 2025

For Vivo Bio Tech Limited



M. Kalyan Ram
Whole Time Director
DIN:02012580

Notes:

1. The above Un-Audited Financial Results for the Third Quarter and Nine Months ended December 31, 2024, were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on January 09, 2025.
2. The Un-Audited Financial Results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of Companies Act, 2013 ('The Act') read with relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
3. The Consolidated Results include results of all subsidiaries, viz., Vivobio Labs Private Limited, Vivobio Discovery Services Private Limited, Surlogic Life Consultancy Private Limited and Vivobio Consulting Services Private Limited (Formerly Donakanti Consulting Services Private Limited).
4. Company has Four (4) subsidiaries, viz., Vivobio Labs Private Limited, Vivobio Discovery Services Private Limited, Surlogic Life Consultancy Private Limited and Vivobio Consulting Services Private Limited and has no associate/joint venture company(ies), as on December 31, 2024.
5. The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required.
6. The above financial results are available on the stock exchange website www.bseindia.com and company's website www.vivobio.com.
7. Previous year's/period's figures are rearranged/ regrouped wherever necessary.

Date: January 09, 2025

Place: Hyderabad

For Vivo Bio Tech Limited


M. Kalyan Ram
Whole Time Director
DIN: 02012580





P. MURALI & Co.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. T.G, INDIA.

Tel. : (91-40) 2332 6666, 2331 2554
(91-40) 2339 3967, 2332 1470
(91-40) 2332 2119, 2331 7032
Fax : (91-40) 2339 2474
Email : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review report to
The Board of Directors
VIVO BIO TECH LIMITED

We have reviewed the accompanying statement of unaudited standalone financial results of M/s. **VIVO BIO TECH LIMITED** (the "Company") for the quarter ended 31 December, 2024 and for the period from 01 April 2024 to 31 December 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ('Ind AS 34,') prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



P. MURALI & Co.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. T.G, INDIA.

Tel. : (91-40) 2332 6666, 2331 2554
(91-40) 2339 3967, 2332 1470
(91-40) 2332 2119, 2331 7032
Fax : (91-40) 2339 2474
Email : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.,
Chartered Accountants
FRN: 007257S



M V Joshi
Partner
M. No. 024784
UDIN: 25024784BMIXQS1429

Place: Hyderabad
Date: 09.01.2025



P. MURALI & Co.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. T.G, INDIA.

Tel. : (91-40) 2332 6666, 2331 2554
(91-40) 2339 3967, 2332 1470
(91-40) 2332 2119, 2331 7032
Fax : (91-40) 2339 2474
Email : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com


Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review report to
The Board of Directors
VIVO BIO TECH LIMITED**

We have reviewed the accompanying statement of unaudited consolidated financial results of **VIVO BIO TECH LIMITED** (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended 31 December, 2024 and for the period from 01 April 2024 to 31 December 2024 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





P. MURALI & Co.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. T.G, INDIA.

Tel. : (91-40) 2332 6666, 2331 2554
(91-40) 2339 3967, 2332 1470
(91-40) 2332 2119, 2331 7032
Fax : (91-40) 2339 2474
Email : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities which are audited by us:

1. Vivo Bio Labs Private Limited
2. Vivo Bio Discovery Services Private Limited
3. Surlogic Life Consultancy Private Limited
4. Vivo Bio Consulting Services Private Limited (Formerly known as Donakanti Consultancy Services Private Limited)

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.


For P. Murali & Co.
Chartered Accountants
FRN: 007257S


M V Joshi

Partner

M.No. 024784

UDIN: 25024784BMIXQT2465



Place: Hyderabad

Date: 09.01.2025.